NATCO Pharma Limited (NATCOPHARM.BO)
INR 771.25
(0.63%)
INR 771.25
(0.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.79 Billion INR | 69.1% |
| 2022 | 10.4 Billion INR | 210.09% |
| 2021 | 3.62 Billion INR | -51.24% |
| 2020 | 7.09 Billion INR | 1.42% |
| 2019 | 6.9 Billion INR | -25.81% |
| 2018 | 9.25 Billion INR | -6.11% |
| 2017 | 9.68 Billion INR | 34.46% |
| 2016 | 6.97 Billion INR | 154.54% |
| 2015 | 2.83 Billion INR | 26.14% |
| 2014 | 2.13 Billion INR | 15.95% |
| 2013 | 1.96 Billion INR | 20.58% |
| 2012 | 1.5 Billion INR | 36.67% |
| 2011 | 1.16 Billion INR | 13.93% |
| 2010 | 934.93 Million INR | -9.96% |
| 2009 | 1.14 Billion INR | 23.78% |
| 2008 | 925.6 Million INR | 20.4% |
| 2007 | 768.74 Million INR | 25.7% |
| 2006 | 611.54 Million INR | 8.63% |
| 2005 | 562.97 Million INR | 32.29% |
| 2004 | 425.57 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 8.04 Billion INR | 58.15% |
| 2023 Q3 | 3.05 Billion INR | -37.4% |
| 2023 Q1 | 5.47 Billion INR | 50.84% |
| 2023 Q2 | 4.87 Billion INR | -11.01% |
| 2023 Q4 | 4.97 Billion INR | 63.0% |
| 2023 FY | - INR | 69.1% |
| 2022 Q3 | 1.26 Billion INR | 9.41% |
| 2022 Q4 | 3.63 Billion INR | 186.58% |
| 2022 FY | - INR | 210.09% |
| 2022 Q1 | 4.29 Billion INR | 4719.35% |
| 2022 Q2 | 1.15 Billion INR | -73.04% |
| 2021 Q4 | -93 Million INR | -107.05% |
| 2021 Q1 | 1.26 Billion INR | 26.67% |
| 2021 FY | - INR | -51.24% |
| 2021 Q2 | 1.08 Billion INR | -14.43% |
| 2021 Q3 | 1.32 Billion INR | 21.66% |
| 2020 Q1 | 1.89 Billion INR | 39.46% |
| 2020 Q2 | 3.02 Billion INR | 59.17% |
| 2020 Q3 | 1.13 Billion INR | -62.5% |
| 2020 Q4 | 1 Billion INR | -11.65% |
| 2020 FY | - INR | 1.42% |
| 2019 Q3 | 1.59 Billion INR | -4.78% |
| 2019 FY | - INR | -25.81% |
| 2019 Q4 | 1.36 Billion INR | -14.67% |
| 2019 Q2 | 1.67 Billion INR | -21.1% |
| 2019 Q1 | 2.12 Billion INR | 20.49% |
| 2018 Q4 | 1.76 Billion INR | -23.95% |
| 2018 Q3 | 2.31 Billion INR | -11.06% |
| 2018 Q2 | 2.6 Billion INR | 2.76% |
| 2018 FY | - INR | -6.11% |
| 2018 Q1 | 2.53 Billion INR | -37.16% |
| 2017 FY | - INR | 34.46% |
| 2017 Q1 | 1.4 Billion INR | -41.75% |
| 2017 Q4 | 4.03 Billion INR | 35.41% |
| 2017 Q2 | 1.27 Billion INR | -9.06% |
| 2017 Q3 | 2.97 Billion INR | 133.83% |
| 2016 Q4 | 2.4 Billion INR | -9.69% |
| 2016 Q1 | 824 Million INR | -11.97% |
| 2016 Q3 | 2.66 Billion INR | 146.57% |
| 2016 Q2 | 1.08 Billion INR | 31.07% |
| 2016 FY | - INR | 154.54% |
| 2015 Q4 | 936 Million INR | 40.94% |
| 2015 FY | - INR | 26.14% |
| 2015 Q3 | 664.1 Million INR | 10.19% |
| 2015 Q2 | 602.7 Million INR | 1.93% |
| 2015 Q1 | 591.3 Million INR | 20.75% |
| 2014 Q4 | 489.7 Million INR | -10.8% |
| 2014 Q2 | 620.4 Million INR | 5.71% |
| 2014 Q1 | 586.9 Million INR | 30.8% |
| 2014 FY | - INR | 15.95% |
| 2014 Q3 | 549 Million INR | -11.51% |
| 2013 Q2 | 454.6 Million INR | -5.65% |
| 2013 Q3 | 551.9 Million INR | 21.4% |
| 2013 FY | - INR | 20.58% |
| 2013 Q1 | 481.8 Million INR | 40.02% |
| 2013 Q4 | 448.7 Million INR | -18.7% |
| 2012 Q1 | 307.6 Million INR | 38.11% |
| 2012 FY | - INR | 36.67% |
| 2012 Q2 | 444.1 Million INR | 44.38% |
| 2012 Q4 | 344.08 Million INR | -32.76% |
| 2012 Q3 | 511.7 Million INR | 15.22% |
| 2011 Q3 | 315 Million INR | -0.41% |
| 2011 FY | - INR | 13.93% |
| 2011 Q2 | 316.3 Million INR | 0.0% |
| 2011 Q4 | 222.71 Million INR | -29.3% |
| 2010 FY | - INR | -9.96% |
| 2009 FY | - INR | 23.78% |
| 2008 FY | - INR | 20.4% |
| 2007 FY | - INR | 25.7% |
| 2006 FY | - INR | 8.63% |
| 2005 FY | - INR | 32.29% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -95.441% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 69.581% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -173.865% |
| Granules India Limited | 8.6 Billion INR | -118.449% |
| Indoco Remedies Limited | 2.64 Billion INR | -610.035% |
| Achyut Healthcare Limited | 524 Thousand INR | -3586732.061% |
| Ajanta Pharma Limited | 12.56 Billion INR | -49.577% |
| Alkem Laboratories Limited | 24.19 Billion INR | 22.319% |
| Alpa Laboratories Limited | 86.12 Million INR | -21722.425% |
| Brooks Laboratories Limited | 41.72 Million INR | -44941.699% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -697.48% |
| Bajaj HealthCare Limited | 444.51 Million INR | -4128.194% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -1170.765% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 78.709% |
| Eris Lifesciences Limited | 6.98 Billion INR | -169.021% |
| FDC Limited | 4.4 Billion INR | -326.995% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -65.687% |
| Gufic Biosciences Limited | 1.48 Billion INR | -1169.516% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -173.914% |
| Ipca Laboratories Limited | 13.29 Billion INR | -41.321% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -5710.61% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 22819.306% |
| Lasa Supergenerics Limited | -65.08 Million INR | 28979.84% |
| Laurus Labs Limited | 8 Billion INR | -134.761% |
| Lupin Limited | 36.96 Billion INR | 49.161% |
| Mankind Pharma Limited | 28.09 Billion INR | 33.101% |
| Medicamen Biotech Limited | 245.66 Million INR | -7550.818% |
| Medico Remedies Limited | 150.37 Million INR | -12398.504% |
| Megasoft Limited | 284.73 Million INR | -6500.967% |
| Piramal Pharma Limited | 13.05 Billion INR | -43.963% |
| RPG Life Sciences Limited | 1.28 Billion INR | -1366.641% |
| Sigachi Industries Limited | 883.39 Million INR | -2027.58% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 86.416% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -301.845% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -4268.127% |
| Unichem Laboratories Limited | 742.35 Million INR | -2431.804% |
| Wanbury Limited | 985.49 Million INR | -1807.173% |
| Windlas Biotech Limited | 781.72 Million INR | -2304.314% |
| ZIM Laboratories Limited | 462.09 Million INR | -3967.328% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 66.57% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 603.716% |
| Divi's Laboratories Limited | 25.43 Billion INR | 26.091% |
| Hester Biosciences Limited | 539.47 Million INR | -3383.975% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -523.507% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -2653.693% |
| Bal Pharma Limited | 345.59 Million INR | -5338.494% |
| Strides Pharma Science Limited | 3.76 Billion INR | -399.246% |
| Venus Remedies Limited | 711.8 Million INR | -2540.485% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -380.762% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -1101.888% |
| Shilpa Medicare Limited | 2.58 Billion INR | -626.241% |
| Aarti Drugs Limited | 3.24 Billion INR | -478.552% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -621.054% |
| Suven Life Sciences Limited | -992.78 Million INR | 1993.169% |
| Ind-Swift Limited | 1.06 Billion INR | -1664.679% |
| Valiant Laboratories Limited | 12.73 Million INR | -147439.053% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -101.343% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 766.041% |
| Themis Medicare Limited | 562.6 Million INR | -3240.698% |
| Hikal Limited | 2.69 Billion INR | -598.12% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 46.315% |
| Sequent Scientific Limited | 549.8 Million INR | -3318.516% |
| Novartis India Limited | 1.26 Billion INR | -1380.737% |
| Wockhardt Limited | 1.08 Billion INR | -1640.278% |
| Jubilant Pharmova Limited | 8 Billion INR | -134.761% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -143790.675% |
| Neuland Laboratories Limited | 4.74 Billion INR | -295.836% |
| Morepen Laboratories Limited | 1.72 Billion INR | -988.963% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -6439.097% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -10643.315% |